Phaseline

Targets › IDUA

IDUA (Alpha-L-iduronidase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jan 2035.

Lysosomal hydrolase responsible for the degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. (UniProt, P35475)

Open in Phaseline: the race on IDUA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Orchard TherapeuticsAutologous CD34+ hematopoietic stem and progenitor cells genetically modified wi
Lentiviral vector-mediated gene therapy delivering human α-L-iduronidase (IDUA) cDNA to au
IDUAPhase 1Mucopolysaccharidosis IHJan 2035

Conditions

Mucopolysaccharidosis IH (1)

Modalities

other (1)

Companies

Orchard Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.